

Special Issue

Hybrid Drugs: Design and Applications

Message from the Guest Editors

A general belief that agents modulating multiple biological targets could outperform single target drugs paved the way for the introduction of molecular hybridization as an efficient technique in drug discovery and development. The goal of this approach is to combine two (or more) pharmacophoric/bioactive subunits into a new, single chemical entity known as a hybrid molecule. When compared to the parent drugs, the new hybrid molecule may have higher affinity and efficacy, a modified selectivity profile with improved pharmacokinetic and pharmacodynamic restrictions, dual or multiple modes of action, reduced undesirable side effects, decreased drug–drug interactions, reduced emergence or spread of drug resistance in pathogens, and lower cost. The major challenges in developing new molecular hybrids that target complex diseases include selecting the right target combination and achieving balanced activity while retaining drug-like properties. Nonetheless, hybridization is gaining popularity in academia and industry as a valuable tool for developing new drugs for diseases such as cancer, malaria, tuberculosis, Alzheimer's, and others.

Guest Editors

Dr. Parvesh Singh

School of Chemistry, University of KwaZulu-Natal, Durban, South Africa

Dr. Vipin Kumar

Department of Chemistry, Guru Nanak Dev University, Amritsar, India

Deadline for manuscript submissions

closed (15 January 2023)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/111147

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)